Drug labels must now reveal where ingredients come from—in five years
S. 3788 — CLEAR LABELS Act · Filed by Rick Scott (R-FL) · 12 cosponsors · Introduced Feb 5, 2026 · Reported out
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill requires drug manufacturers to label all medications with the name and location of the original manufacturer of active ingredients and finished products, plus any packers or distributors. The FDA can fine companies up to 25% of a drug lot's value for non-compliance, though it must consider company size, prior notice, and good-faith correction efforts. The requirement takes effect 5 years after enactment.
Why we flagged it
The bill's core mechanism is a labeling requirement designed to increase public visibility into pharmaceutical sourcing and manufacturing origins. This is a transparency and consumer-protection measure, not a subsidy, carve-out, or deregulation.
What the text implies
- The 5-year phase-in may allow manufacturers to clear existing inventory without compliance, delaying full transparency benefits for half a decade.
- FDA discretion to treat noncompliance as 'misbranding' rather than mandatory criminal violation may result in inconsistent enforcement depending on agency priorities and resources.
- Coordination with U.S. Customs and Border Protection (Section 4) could create dual-reporting burdens if the agencies do not align requirements, or conversely, may enable information-sharing that strengthens counterfeit detection.
- The definition of 'original manufacturer' (majority of significant manufacturing phases) may be ambiguous for contract manufacturers or complex supply chains, creating compliance uncertainty.
- Trade secret protections (Section 5) may limit public access to supplier information even after labeling requirements take effect, reducing transparency benefits for consumers and researchers.
Section numbers refer to the bill text the analysis read — linked under Primary records below.
Who it affects
Ordinary citizens gain transparency about drug sourcing and supply chains, enabling better informed decisions and helping identify counterfeit or contaminated products. The 5-year implementation window and good-faith correction provisions reduce compliance burden on manufacturers, while FDA discretion to assess penalties (rather than mandatory criminal prosecution) balances accountability with practical enforcement.
Who stands to gain
- Domestic pharmaceutical manufacturers (compliance cost offset by competitive advantage in transparen
- Pharmaceutical supply chain software vendors (tracking and labeling systems)
- Contract manufacturers with clear ownership of manufacturing phases (reduced ambiguity under the bil
Named in the bill
FDA (Food and Drug Administration), U.S. Customs and Border Protection, Pharmaceutical manufacturers, Active pharmaceutical ingredient (API) suppliers, Drug packers and distributors
Where it stands
12 cosponsors: 11 Republicans, 1 Democrats.
- Feb 5, 2026 — Introduced · Congress.gov: “Introduced in Senate”
- Feb 5, 2026 — Referred to Senate Committee on Banking, Housing, and Urban Affairs and Senate Committee on Health, Education, Labor, and Pensions · Congress.gov: “Read twice and referred to the Committee on Health, Education, Labor, and Pensions”
- Mar 19, 2026 — Hearing held · Congress.gov: “Committee on Health, Education, Labor, and Pensions. Hearings held”
- Jul 22, 2026 — Reported out of committee · Congress.gov: “Committee on Health, Education, Labor, and Pensions. Ordered to be reported with an amendment in the nature…”
Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.
Money around this bill
13 lobbying clients named this bill on 14 disclosure filings across 2 quarters, Mar 2026 to Jun 2026. Those filings disclosed $17,239,750 in lobbying spend. A filing names 14 bills on average, so that figure is what each filing reported, not a share belonging to this bill.
More lobbying clients named this bill than 94% of bills with at least one filing.
Rick Scott, the sponsor, reported $69,750 in PAC receipts in the 2026 cycle.
- Pharmaceutical Research and Manufacturers of America — $7,360,000 on 1 filing
- American Hospital Association — $4,470,000 on 1 filing
- Amgen Inc — $2,440,000 on 1 filing
- Gsk (fka Glaxosmithkline Inc.) — $890,000 on 1 filing
- Association for Accessible Medicines — $870,000 on 1 filing
Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.
How this was measured
Analysis — Quorum's AI read the bill text published by Congress.gov (4,583 characters) on Jul 9, 2026. Section numbers in the findings refer to that text, linked below; transparency and hidden-provision scores are compared against the median of 16,222 analysed bills.
Status and sponsors — Congress.gov's bill record — actions, committee referrals and cosponsors — loaded nightly. The timeline shows status changes, not every procedural action.
Money — Senate Lobbying Disclosure Act filings whose specific-issue field names this bill for quarters ending Mar 2026 to Jun 2026. A filing's amount is reported whole beside the median number of bills a filing names; it is never divided across them. PAC receipts are FEC-reported contributions to the sponsor's candidate committee in the 2026 cycle.
As of — lobbying records through Jul 20, 2026 · page rendered 2026-10-20.
“Drug labels must now reveal where ingredients come from—in five years” QuorumCivic. https://share.quorumcivic.app/bill/119/s3788 Report an error
The week in bills
One email, Sunday: what Congress passed, what it changed, and who paid.
One link arrives to confirm the address. It is used for this email and nothing else, and every issue carries an unsubscribe link.